— Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics’ C-IBS Clinical Advisory Board —
ROCKVILLE, Md., Aug. 13, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company’s irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).
Synthetic Biologics’ CEO, Jeffery Riley, and Joseph Sliman, M.D., M.P.H., Senior Vice President, Clinical & Regulatory Affairs, will provide an overview of the anticipated clinical and regulatory pathway for SYN-010 to reduce the impact of methane producing organisms on C-IBS, including plans to file an Investigational New Drug (IND) application and initiate a Phase II dose-discovery and proof-of-mechanism clinical study in the second half of 2014. Keynote speaker, Dr. Mark Pimentel will discuss his groundbreaking work that led to the discovery of SYN-010, including the association between the overproduction of methane gas by microorganisms in the gut and conditions such as C-IBS, as well as further detail for SYN-010 itself.
Tuesday, September 16, 2014
9:00 a.m. to 11:00 a.m. EDT
Grand Hyatt New York Hotel, New York City
This event will be accessible via live webcast, to be made available on Synthetic Biologics’ website.
Keynote Speaker Bio:
Dr. Mark Pimentel is Director, GI Motility Program and Laboratory, and Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles, California. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical studies in IBS, and the relationship between gut flora composition and human disease. Dr. Pimentel is the lead investigator for Synthetic Biologics’ C-IBS program, as well as the Chairman of the Company’s C-IBS Clinical Advisory Board.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding Synthetic Biologics’ plans to file an Investigational New Drug (IND) application and initiate a Phase II dose-discovery and proof-of-mechanism clinical study in the second half of 2014. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, the IND filing and clinical trial not being commenced when planned and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Logo – https://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.
Released August 13, 2014